In vitro Evaluation of the Antibacterial Activity of the Combination of Avibactam and β-Lactams Against Highly Virulent Carbapenem-Resistant Klebsiella pneumoniae

体外评价阿维巴坦与β-内酰胺类抗生素联合用药对高毒力耐碳青霉烯类肺炎克雷伯菌的抗菌活性

阅读:1

Abstract

PURPOSE: To study the resistance of carbapenem-resistant Klebsiella pneumoniae to β-lactams combined with avibactam, as well as the distribution of resistance and virulence genes, and to analyze the clinical characteristics of infected patients. METHODS: Antibiotic susceptibility was examined using the trace broth dilution method. Carbapenem-resistance genes, porins, and virulence genes were identified using PCR. Strain adhesion was assessed through wire-drawing experiments, and clinical data from infected patients were collected. RESULTS: Among 80 CRKP strains, 93.8% harboured blaKPC-2, and 1.3% harboured both blaKPC-2 and blaNDM. Some strains lacked OMPK35 (6.2%) and OMPK36 (10%). Virulence genes ycfM, entB, fimH, irp-1, and prmpA2 were prevalent. The combination of carbapenems, cephalosporins, and aztreonam with avibactam significantly lowered MIC values compared to single drugs (P<0.01). Significant differences in MIC were noted between low and high avibactam concentrations (P<0.05). CONCLUSION: CRKP harbouring virulence genes poses significant risks. Combining carbapenems, cephalosporins, and avibactam enhances antibacterial activity against CRKP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。